Cosimo Loseto
MD
Hematologist, Lymphoma Section
👥Biography 个人简介
Cosimo Loseto participated in clinical research evaluating zanubrutinib in relapsed/refractory marginal zone lymphoma, including contributions to the MAGNOLIA trial that led to FDA approval of zanubrutinib for this indication. His research focuses on B-cell receptor pathway inhibition across MZL subtypes and identifying patient populations most likely to benefit from BTK inhibitor therapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Cosimo Loseto 的研究动态
Follow Cosimo Loseto's research updates
留下邮箱，当我们发布与 Cosimo Loseto（IRCCS Istituto Tumori Giovanni Paolo II）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment